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PURPOSE. To analyze the association between skin autofluorescence (sAF), estimating tissue
accumulation of advanced glycation end-products (AGEs), and open angle glaucoma (OAG) in
an elderly population.
METHODS. The Antioxydants, Lipides Essentiels, Nutrition and maladies OculaiRes (ALIENOR)
study is an on-going epidemiologic population-based study on age-related eye diseases. In
2009 to 2010, 624 subjects, aged 74 years or older, were recruited. All subjects underwent a
complete eye examination, including optic disc color photography and spectral-domain
optical coherence tomography (SD-OCT) examination. Sociodemographic and medical
history data were collected using standardized questionnaires. Glaucoma diagnosis was
made using optic nerve head retinophotography and International Society for Epidemiologic
and Geographical Ophthalmology criteria. sAF was measured with a noninvasive autofluo-
rescence reader in 467 subjects.
RESULTS. Of subjects, 455 had complete data, 424 were classified as controls, and 31 classified
as OAG. Mean age was 82.3 6 4.3 years, mean and median sAF were 2.8 6 0.7 and 2.7
arbitrary units (AU), respectively. In a multivariate analysis, higher sAF values (‡2.7 AU) were
associated with OAG (odds ratio [OR] ¼ 2.28, 95% Confidence Interval [CI]: 1.03; 5.04).
Other variables significantly associated with OAG were age (OR ¼ 1.10, 95%CI: 1.00; 1.21),
glaucoma family history (OR ¼ 2.83, 95%CI: 1.14; 7.01) and smoking (1–20 pack-years [OR ¼
3.31, 95%CI: 1.18; 9.26]; ‡20 pack-years [OR ¼ 3.85, 95%CI: 1.42; 10.46]).
CONCLUSIONS. Higher level of sAF, which may act as a long-term biomarker of metabolic
memory, and smoking are independently associated with an increased risk of glaucoma. Long-
term accumulation of AGEs, a marker of oxidative stress, could play a role in the pathogenesis
of glaucomatous chronic optic neuropathy.
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Glaucoma is a neurodegenerative disease defined by aprogressive loss of optic nerve axons and retinal ganglion
cells resulting in a characteristic enlargement of the optic nerve
head cup and associated visual field defects.1 It remains the
most common cause of irreversible blindness worldwide by
affecting more than 60.5 million people in 2010 and with an
estimated increasing prevalence up to 111.8 million in 2040.2,3
Although IOP is an important contributing factor in neuro-
retinal rim thinning observed in POAG, the pathophysiologic
process leading to a progressive degeneration of retinal
ganglion cells may be more complex. Local microvascular
blood flow dysfunction, neurotrophic factors, modified biome-
chanical response of lamina cribrosa to an increase in IOP, or
oxidative stress mechanisms can be associated.4–7
Advanced glycation end-products (AGEs) represent a group
of various proteins, lipids, or nucleic acids that become
glycated as a result of a chronic exposure to glucose or other
reducing sugars and have been described as one component of
oxidative stress generation in tissues. AGEs result from a
nonenzymatic reaction between reducing sugars and amino
groups of proteins, lipids, or nucleic acids; thus, giving rise to a
Schiff base and glycation of these molecules. This early
modification is reversible but glycated molecules slowly
rearrange by rehydration, fragmentation, or cyclization reaction
in irreversible Amadori products leading to the formation of
AGEs, which accumulate in long-lived proteins, such as
collagen.8–10 Formation and accumulation of AGEs are not only
associated with diabetes mellitus, characterized by a higher
concentration of carbonyl substrates in tissue, but are also
generated in physiologic conditions, and are thus involved in
the natural ageing process.8 Furthermore, they can also
influence the incidence or progression of several age-related
chronic diseases, such as chronic kidney disease, cardiovascular
disease, heart failure, and dementia or other neurodegenerative
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diseases.11–16 Additionally, some experimental studies have
demonstrated that AGEs accumulate in ocular tissues and may
be involved in the pathophysiologic process of eye diseases,
such as cataract, diabetic retinopathy, or AMD.17–19
Accumulation of AGEs can be estimated with skin
autofluorescence (sAF) measurements using a noninvasive
device.20,21 This method uses fluorescence properties of AGEs
and has been validated with specific AGEs analyzed in skin
biopsies obtained from the same site and showing a high
correlation between sAF and skin AGEs. Additionally, blood or
urine circulating AGEs measurements do not necessarily reflect
their tissue level and sAF has been proposed as a better
biomarker of cumulative metabolic stress by evaluating AGEs
accumulation in tissues and particularly in skin collagen having
a mean half-life of 15 years.10,21 Several studies have also
demonstrated an association between higher level of sAF and
some chronic diseases as diabetes mellitus and associated
complications, chronic kidney disease, some cardiovascular
diseases, arterial stiffness, and peripheral arterial disease or
some neurologic diseases.22–32 Furthermore, as sAF reflects
tissue accumulation of AGEs in long-lived proteins, sAF has also
been described as a marker of metabolic memory, defined as
the cumulative effect of metabolic activity over a long period,
and a strong predictive factor of cardiovascular or end-stage
renal disease complications.33–37
Many structures of the eye, including conventional and
uveoscleral aqueous outflow pathways or some structures of
the optic nerve head, are mainly composed of collagen or other
extracellular matrix molecules with a slow turnover time.
Whereas glaucoma is an age-related chronic neurodegenerative
disease and oxidative stress may contribute to its pathophys-
iologic process, the association between AGEs and glaucoma
received little attention.5,38–40 Hence, only a few experimental
studies have reported a higher accumulation of AGEs in the
optic nerve head, in the retinal ganglion cell layer, in the glia
and in the retinal distribution of Müller cells or around blood
vessels, thus suggesting a potential role in the pathogenesis of
glaucoma.41,42 However, to date, AGEs have never been
evaluated in vivo and in a general population as a potential
risk factor for glaucoma.
We therefore investigated the associations between sAF and
glaucoma in a population-based study of elderly subjects having
a long history of accumulation of AGEs in skin collagen and in
which metabolic activity had been recorded over a long period.
MATERIALS AND METHODS
The Antioxydants, Lipides Essentiels, Nutrition and maladies
OculaiRes (ALIENOR) Study is an on-going population-based
epidemiologic study on age-related eye diseases performed at
the University Hospital of Bordeaux. The complete methodol-
ogy of this study was published previously.43–45
Study Population
The main objective of the ALIENOR study was to analyze the
associations of age-related eye diseases with nutritional,
environmental, and vascular factors, or gene polymorphisms.43
Participants were recruited from an on-going population-based
study analyzing risk factors for dementia, the Three-City (3C)
Study.44 In 1999 to 2001, the 3C study randomly recruited
participants aged 65 years or older on electoral rolls from three
French cities (Bordeaux, Dijon, and Montpellier). Participants
were individually contacted and 9294 participants were
recruited, including 2104 from Bordeaux. Since then, all
participants were followed for approximately every 2 years.
The ALIENOR Study consists of eye examinations offered to all
participants of the 3C cohort in Bordeaux since the third
follow-up (2006–2008). Among the 1450 participants enrolled
at this follow-up, 963 (66.4%) accepted the ALIENOR study’s
baseline eye examination. Delcourt et al.43 published demo-
graphic characteristics of participants included at baseline, and
their comparison with nonparticipants.
At the fourth follow-up (2009–2010), a measurement of sAF
was included. Among the 963 participants, 624 (59 deaths, 265
refusals, 15 moves) participated in the ALIENOR study’s
second eye examination. They were aged 74 years or more.
At this follow-up, representativeness of our population sample
has been tested using the database of the National Institute for
Statistics and Economics Studies INSEE (Institut National de la
Statistique et des Etudes Economiques) for the Bordeaux area.
There was no significant difference in age or sex distribution,
residency location, and loneliness index between our popula-
tion sample and data of Bordeaux area population.46
This research was approved by the Ethical committee of
Bordeaux (Comité de Protection des Personnes Sud-Ouest et
Outre-Mer III) in May 2006 and followed the declaration of
Helsinki’s tenets. All participants provided informed written
consent for enrollment in the study.
Eye Examination
All participants underwent an ophthalmologic examination
including a best-corrected visual acuity measurement, a tear
break-up time test, a central corneal thickness measurement
using Pachpen (Accutome, Inc., Malvern, PA, USA), after local
anesthesia with oxybuprocaine eye drops, and an IOP measure-
ment using a noncontact tonometer (KT 800; Kowa, Aichi
Japan). Nonstereoscopic color photography of the macula and
the optic disc were performed using a nonmydriatic retinophoto-
graph (TRC NW6S; Topcon, Inc., Tokyo, Japan). Macula and
optic disc measurements were assessed by spectral-domain
optical coherence tomography (SD-OCT; Spectralis; Heidelberg
Engineering, Germany). All measurements were performed
between 2 PM and 6 PM, including IOP measurements.
Retinal photographs were interpreted in duplicate by two
specially trained technicians. Inconsistencies between the two
interpretations were adjudicated by a glaucoma specialist for
classification of glaucoma and by a retina specialist for
classification of AMD or other retinal diseases. All cases of
glaucoma and retinal disease were reviewed and confirmed by
specialists.
Clinical and Lifestyle Determinants
All clinical and lifestyle determinants were collected at baseline
(1999–2001) and at the fourth follow-up (2009–2010) of the
3C study. Sociodemographic, lifestyle, and medical history data
were collected during a face-to-face interview using a
standardized questionnaire administered by a trained psychol-
ogist or nurse. It included age, sex, educational level, smoking,
hypertension (systolic blood pressure ‡140 mm Hg, diastolic
blood pressure ‡90 mm Hg, or antihypertensive treatment),
body mass index (BMI, [weight (kg)/height2 (m2)]) and an
inventory of all drugs used during the preceding month. Pack-
years of smoking were calculated as numbers of smoking years
3 (mean number of cigarettes per day) ‚ 20.
Plasma glucose and lipids were determined from fasting
blood samples performed at baseline and in 2010. Diabetes was
defined as fasting blood glucose greater than or equal to 7.0
mM or current use of antidiabetic treatment.
Estimated glomerular filtration rate (eGFR) derived from
serum creatinine based on modification of diet in renal disease
equation and chronic kidney disease was defined as an eGFR
inferior to 60 mL/min/1.73 m2.47
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Glaucoma Diagnosis
The methods chosen to diagnose glaucoma in the ALIENOR
study were published in details and used the classification
provided by Foster et al.43,45,48 Briefly, the vertical cup:disc
ratio (VCDR) and the minimal rim:disc ratio were estimated
from optic disc photographs. Participants were classified as
suspects for glaucoma when, in at least one eye, VCDR was
greater than or equal to 0.65 and/or minimal rim:disc ratio less
than or equal to 0.1 or when an asymmetry of VCDR between
eyes greater than or equal to 0.2 was observed. For glaucoma
suspect cases, an additional eye examination was performed by
a glaucoma specialist including a white-on-white visual field
test (Octopus 101; Haag-Streit, Koniz, Switzerland), an
examination of the optic disc by slit-lamp and of the irido-
corneal angle by gonioscopy, and an IOP measurement.
Glaucoma was defined according to three levels of evidence
and all glaucoma cases were classified according to category 1
criteria, except one case with category 2 criteria. The final
classification was reviewed and confirmed by a glaucoma
specialist. All cases of glaucoma were classified as open angle
glaucoma (OAG).
Skin Autofluorescence Measurement
In 2009 to 2010, sAF measurements were performed using the
AGE Reader (DiagnOptics Technologies B.V., Groningen, the
Netherlands) and were expressed in arbitrary units (AU). This
noninvasive device estimates AGEs accumulation by using their
fluorescence properties. A skin surface of approximately 4 cm2
guarded against surrounding light is illuminated on the forearm
with an excitation light source. Autofluorescence is calculated
as the ratio of the emission light intensity per nanometer
(wavelength 420–600 nm) and the reflected excitation light
intensity per nanometer (wavelength 300–420 nm) measured
with a spectrometer. All measurements were performed on a
normal skin site of the volar side of the forearm and without
visible vessels, scars, abnormal pigmentation, or lichenification
of the skin and without any use of skin creams or products. As
recommended by the manufacturer, all measurements were also
performed in a dark environment and at room temperature.
Meerwaldt et al.21 reported a high correlation between sAF
measurements and specific AGEs analyzed in skin biopsies
taken from the same site on the volar side of the forearm. They
also reported that sAF values obtained from the AGE reader
were reproducible with intraindividual measurements per-
formed on one day or with seasonal variation showing Altman
error percentages of 5.03% and 5.87%, respectively.21 Further-
more, reproducibility of sAF measurements was evaluated in
other studies with intraobserver and interobserver coefficients
of variations ranging from 6.2% to 7% and from 3.9% to 8%,
respectively.49,50 Finally, sAF measurements were reliable for a
wide range of native skin colors including Fitzpatrick skin
phototypes from I to IV.51
Additionally, sAF evaluation was performed in triplicate and
the mean of the three values was recorded. Participants with
Fitzpatrick skin phototype V and VI could not be evaluated by
the AGE reader due to darker skin pigmentation causing
ultraviolet reflectance below 10%. Fitzpatrick skin phototype
classification is a standard grading scale on skin pigmentation
and skin response to sun exposure, and ranges from I (very
pale skin, always burns) to V (dark brown skin, very rarely
burns), and VI (darkest brown skin, never burns).
Median sAF value was calculated and participants were
allocated in two groups, those with a sAF value lower than the
median and those with a sAF value superior than or equal to
the median.
Statistical Analysis
Results were presented using means 6 SDs for continuous
variables, and n and percentage for noncontinuous variables.
Participants included in the analysis were compared with
nonincluded participants for demographic characteristics to
assess potential selection bias in the final statistical analysis.
Firstly, associations of demographic and medical character-
istics (independent parameters) with glaucoma (dependent
parameter) were examined with logistic generalized estimating
equations (GEE) models, adjusted for age and sex. GEE models
allow taking into account data from both eyes and their
intraindividual correlations (using an unstructured correlation
matrix).
Secondly, all variables, which were significantly associated
with glaucoma in the age- and sex-adjusted models at P less
than 0.15 were included in a multivariate model. In addition,
age and sex, were forced into all analyses. The associations are
presented as odds ratios (OR) and 95% confidence intervals
(CI). All statistical tests were two-sided and P values less than
0.05 were considered as significant. All statistical analyses were
performed using SAS version 9.3 (procedure GENMOD for the
GEE analysis; SAS Institute, Inc., Cary, NC, USA).
RESULTS
There were 624 participants evaluated at the second follow-up
of the ALIENOR study. Of participants, 169 were excluded
from the analysis: 157 had missing sAF measurements or a
Fitzpatrick skin phototype V or VI, and 12 could not have a
diagnosis of glaucoma due to poor quality of the retinophotog-
raphy and optic disc measurements could not be performed.
Finally, 455 participants were included for analysis.
Table 1 shows comparison of demographic characteristics
between included and nonincluded participants. There was no
significant difference in the distribution of sex or mean age,
family history of glaucoma, IOP, VCDR, medical characteristics,
and smoking between the 2 groups. Prevalence of glaucoma was
similar in the two groups (P ¼ 0.64). At eye examination visit
performed for all glaucoma suspect participants, the mean defect
of the visual field test was 8.91 6 5.50 dB (minimum–maximum
[min–max]: 0.58–24.30) for participants with glaucoma.
Demographic Characteristics and sAF Comparison
Between Glaucoma and Control Groups
Table 2 shows the associations of demographic characteristics,
family history and sAF with glaucoma using GEE models
adjusted for age and sex. Of participants, 424 were included in
the control group and 31 in the glaucoma group. The mean age
was 82.32 6 4.23 years and was not significantly different
between the group with and the group without glaucoma.
Male subjects represented 38.24% (n¼ 174) of the sample and
there was no significant difference between the two groups.
Mean and median sAF values were 2.08 6 0.7 and 2.7 AU
(min–max: 1.2–5.1), respectively. sAF values superior than or
equal to 2.7 AU are significantly associated with a 2.71-
increased risk of having glaucoma (odds ratio [OR]¼ 2.71; 95%
confidence interval [CI]: 1.23; 5.93). The Figure illustrates the
distribution of sAF values in the group with and in the group
without glaucoma. We observed a symmetry of distribution of
sAF values with the median line in the two groups and the
glaucoma group exhibited higher sAF values particularly for
first, second, and third interquartiles of the boxplot.
Family history of glaucoma was associated with a significant
increased risk of having glaucoma with an OR of 2.87 (95%CI:
1.18; 7.01).
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Finally, smokers had a significant higher risk to have
glaucoma than nonsmokers (OR ¼ 2.99 [95%CI: 1.19; 7.58]
for 1 to 20 pack-years exposure and OR ¼ 3.23 [95%CI: 1.27;
8.23] for >20 pack-years exposure).
Medical Characteristics at Baseline (1999–2001)
and at Ophthalmologic Examination (2009–2010)
Between Glaucoma and Controls Groups
Table 3 shows medical characteristics at baseline of the 3C
Study (1999–2001) and at ophthalmologic examination (2009–
2010) using GEE models adjusted for age and sex.
Hypertension was not significantly associated with an
increased risk of glaucoma whether at baseline or at
ophthalmologic examination (OR ¼ 0.65 [95%CI: 0.29; 1.42]
and OR ¼ 0.64 [95%CI: 0.25; 1.65], respectively).
We did not observe any significant increased risk of
glaucoma for subjects with chronic kidney disease whether
at baseline or at ophthalmologic examination (OR ¼ 1.78
[95%CI: 0.67; 4.71] and OR ¼ 1.71 [95%CI: 0.66; 4.43],
respectively).
Finally, the glycemic status defined either by a diagnostic of
diabetes mellitus or glycated hemoglobin (HbA1c) greater than
or equal to 7.5 mM or blood glucose greater than or equal to
7.0 mM was not associated with an increased risk of glaucoma
either at baseline or during the follow-up.
Multivariate Models of Associations of Glaucoma
With Risk Factors
Table 4 shows the multivariate model of determinants
associated with glaucoma using GEE models.







(N ¼ 169) P Value
Age, y (SD) 82.19 (4.25) 82.32 (4.23) 81.82 (4.32) 0.19
Sex: male subjects (%) 233 (31.34) 174 (38.24) 59 (34.91) 0.45
Glaucoma, n (%) (n ¼ 606) 43 (7.1) 31 (6.8) 12 (7.95) 0.64
Family history of glaucoma, n (%) (n ¼ 622) 83 (13.34) 57 (12.56) 26 (15.48) 0.34
Vertical cup disc ratio (SD) (n ¼ 613) 0.43 (0.09) 0.43 (0.08) 0.42 (0.09) 0.14
Minimal rim ratio (SD) (n ¼ 613) 0.21 (0.04) 0.21 (0.04) 0.21 (0.05) 0.63
IOP, mm Hg (SD) (n ¼ 617) 13.67 (2.18) 13.68 (2.21) 13.69 (2.08) 0.90
Hypertension* (n ¼ 603) 508 (84.25) 371 (84.70) 137 (83.03) 0.62
Chronic kidney disease† (n ¼ 506) 208 (41.11) 149 (40.49) 59 (42.75) 0.65
HBA1c ‡7.5% (n ¼ 501) 15 (2.99) 11 (3.01) 4 (2.94) 1.00
Diabetes mellitus‡ (n ¼ 519) 86 (16.57) 68 (17.99) 18 (12.77) 0.16
Fasting blood glucose ‡7.0 mM (n ¼ 495) 34 (6.87) 25 (6.93) 9 (6.72) 0.94
Smoking, pack/y (n ¼ 619) no 400 (64.62) 294 (65.19) 106 (63.10) 0.28
1–20 113 (18.26) 76 (16.85) 37 (22.02)
‡20 106 (17.12) 81 (17.96) 25 (14.88)
* Systolic blood pressure ‡140 mm Hg or diastolic blood pressure ‡90 mm Hg, or antihypertensive medication.
† eGFR <60 mL/min/1.73 m2.
‡ Diabetes: fasting plasma glucose ‡7 mM and/or use of antidiabetic medication.






(N ¼ 31) OR* 95%CI* P Value*
Age, y (SD) 82.32 (4.23) 82.26 (4.22) 83.14 (4.35) 1.08 0.99; 1.18 0.08
Sex: male 174 (38.24) 161 (37.97) 13 (41.94) 1.67 0.77; 3.67 0.21
Family history of glaucoma (n ¼ 454) 57 (12.56) 49 (11.58) 8 (25.81) 2.87 1.18; 7.01 0.02
Vertical cup disc ratio
Mean (SD) 0.43 (0.08) 0.42 (0.07) 0.61 (0.10) 7.56 4.76; 12.00 <0.0001
‡0.65 10 (2.20) 0 (0.00) 10 (100.00) NA NA
‡0.70 7 (1.54) 0 (0.00) 7 (100.00) NA NA
Minimal rim width
Mean (SD) 0.21 (0.04) 0.21 (0.04) 0.14 (0.05) 0.13 0.06; 0.28 <0.0001
0.1 9 (1.98) 0 (0.00) 9 (100.00) NA NA
Smoking, pack/y
(n ¼ 451)
No 294 (65.19) 280 (66.67) 14 (45.16) 1.00 (Ref)
1–20 76 (16.85) 68 (16.19) 8 (25.81) 2.99 1.19; 7.58 0.02
‡20 81 (17.96) 72 (17.14) 9 (29.03) 3.23 1.27; 8.23 0.01
sAF ‡2.7, AU 243 (53.41) 221 (52.12) 22 (70.97) 2.71 1.23; 5.93 0.01
Ref, reference; NA, not applicable.
Results in bold are statistically significant (P < 0.05).
* Estimated using GEE logistic regression adjusted for age and sex.
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After adjustment with age, sex, family history of glaucoma,
smoking, chronic kidney disease, and blood glucose greater
than or equal to 7.0 mM, sAF values greater than or equal to 2.7
AU remained strongly associated with glaucoma and an odds
ratio of 2.28 (95%CI: 1.03; 5.04).
Age and family history of glaucoma were significantly
associated with glaucoma (OR ¼ 1.1 [95%CI: 1.00; 1.21] and
OR ¼ 2.83 [95%CI: 1.14; 7.01], respectively), whereas the
association with sex was not statistically significant (OR¼ 0.97
[95%CI: 0.42; 2.22]).
In this model, association between smoking and glaucoma
remained significant with an increased risk up to 3.31 (95%CI:
1.18; 9.26) for the group 1 to 20 pack-years exposure and to
3.85 (95%CI:1.42; 10.46) for the group of 20 or more pack-
years exposure.
Finally, subjects with blood glucose greater than or equal to
7.0 mM tended to have an increased risk of having glaucoma
with an OR of 2.82 (95%CI: 0.81; 9.84) without reaching
statistical significance.
DISCUSSION
The current study is the first population-based study showing
that higher levels of sAF are independently associated with
glaucoma in a large and unselected population of elderly
people. By reflecting accumulation of AGEs in long-lived
proteins of the skin, this result also suggests that long-term
accumulation of AGEs may contribute to the pathogenic
process of glaucomatous neuropathy.
Several studies have also demonstrated that increased sAF
values increased the incidence or progression of some age-
related chronic diseases.22–32 In diabetic patients, sAF was
described as a marker of chronic hyperglycemia for a longer
lifetime period than HbA1c and was also independently
associated with micro- and macrovascular complica-
tions.27,30,52 In nondiabetic patients, increased sAF was also
associated with increased arterial stiffness, peripheral arterial
disease, and coronary artery calcifications.23,25,37 sAF was also
associated with brain atrophy using magnetic resonance
imaging, impaired cognitive functions, or some neurologic
diseases.26,29,32 Finally and more interestingly, sAF was
proposed as a long-term metabolic marker and a predictive
factor of diseases or complications.33–37 Indeed, we showed
that sAF levels reflect glycemic and renal status 10 years
before, and other prospective studies found that sAF predicts 5-
year amputation in patients with peripheral arterial disease and
is associated with a higher risk of mortality in patients with






(N ¼ 31) OR* 95%CI* P Value*
Medical characteristics at baseline (1999–2001)
Hypertension† 335 (73.63) 314 (74.06) 21 (67.74) 0.65 0.29; 1.42 0.28
Chronic kidney disease‡ (n ¼ 423) 57 (13.48) 52 (13.20) 5 (17.24) 1.78 0.67; 4.71 0.25
HBA1c ‡7.5% (n ¼ 104) 12 (11.54) 10 (10.42) 2 (25.00) 2.74 0.49; 15.40 0.25
Diabetes mellitus§ (n ¼ 422) 32 (7.58) 29 (7.38) 3 (10.34) 1.41 0.40; 5.02 0.60
Fasting blood glucose ‡7.0 mM (n ¼ 420) 16 (3.81) 13 (3.32) 3 (10.34) 3.28 0.86; 12.48 0.08
Medical characteristics at ophthalmologic examination (2009–2010)
Hypertension† (n ¼ 438) 371 (84.70) 347 (85.05) 24 (80.00) 0.64 0.25; 1.65 0.35
Chronic kidney disease‡ (n ¼ 368) 149 (40.49) 137 (39.60) 12 (54.55) 1.71 0.66; 4.43 0.27
HBA1c ‡7.5% (n ¼ 365) 11 (3.01) 10 (2.91) 1 (4.76) 1.68 0.20; 14.23 0.63
Diabetes mellitus§ (n ¼ 378) 68 (17.99) 63 (17.75) 5 (21.74) 1.32 0.47; 3.68 0.59
Fasting blood glucose ‡7.0 mM (n ¼ 361) 25 (6.93) 24 (7.04) 1 (5.00) 0.59 0.08; 4.52 0.61
Results in bold are statistically significant (P < 0.05)
* Estimated using GEE logistic regression models adjusted for age and sex.
† Systolic blood pressure ‡140 mm Hg or diastolic blood pressure ‡90 mm Hg, or antihypertensive medication.
‡ eGFR < 60 mL/min/1.73 m2.
§ Diabetes: fasting plasma glucose ‡7 mM and/or use of antidiabetic medication.
TABLE 4. Multivariate Models of Associations of Glaucoma With Risk
Factors (N¼ 800 eyes)
OR* 95%CI* P Value*
Age 1.10 1.00; 1.21 0.04
Sex 0.97 0.42; 2.22 0.94
Family history of glaucoma 2.83 1.14; 7.01 0.03
Smoking, pack/y
No Ref Ref
1–20 3.31 1.18; 9.26 0.02
‡20 3.85 1.42; 10.46 0.008
sAF ‡2.7 AU 2.28 1.03; 5.04 0.04
Chronic kidney disease†
at baseline
1.24 0.45; 3.39 0.67
Fasting blood glucose at
baseline ‡7.0 mM
2.82 0.81; 9.84 0.10
Results in bold are statistically significant (P < 0.05).
* Estimated using GEE regression logistic models.
† eGFR < 60 mL/min/1.73 m2.
FIGURE. Boxplot showing the distribution of skin autofluorescence
values in the group of participants without glaucoma and the group of
participants with glaucoma.
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end-stage renal disease.33,34,37 All these findings emphasize that
long-term accumulation of AGEs in skin collagen, as measured
with sAF, is associated with the ageing process and could also
lead to several age-related chronic diseases for increased
accumulation of AGEs.
Several factors influence the progressive accumulation of
AGEs in tissues with increasing age, including blood concen-
tration of carbonyl substrates, the glycation reactivity of some
carbonyl intermediates, the permeability of some cells, and the
ability of the biological system to degrade AGEs or the rate of
glomerular filtration.9 But one of the most important factors is
probably the turnover of proteins with a higher accumulation
rate of AGEs observed in long-lived proteins as in crystalline
lens, extracellular matrix, or collagen of tissues; thus,
potentially leading to their modified structure and function
or oxidative stress reaction and tissular damage.10,53,54 Indeed,
some AGEs are able to crosslink with adjacent proteins of the
extracellular matrix as collagen IV or elastin and can stiffen
elastic tissues especially vascular tissue and can also affect cell
adhesion.55 Furthermore, AGEs could also be responsible for
intracellular glycation of proteins leading to modified intracel-
lular enzymatic pathways or altered proteins of mitochondrial
chain transport.56,57 Finally, AGEs can interact with specific
protein binding of cellular membranes and can activate
intracellular signal pathways inducing the expression of
proinflammatory cytokines and chemokines, and thus oxida-
tive stress.58,59 An important extracellular AGE receptor is
receptor for advanced glycation end products (RAGE) and is
expressed at the surface of different tissues and cell types as
smooth muscle cells, endothelial cells, macrophages, and
monocytes or neuronal and microglial cells.60 Through an
activation of the nicotinamide adenine dinucleotide phosphate
oxidase system, the interaction of AGEs and RAGE could
enhance the generation of reactive oxygen species (ROS),
which increases oxidative stress, the formation of AGEs and in
turn sustains AGEs–RAGE interaction thus creating a vicious
circle leading to a chronic oxidative stress in tissues.61
Although glaucoma is a chronic age-related disease, the
association between AGEs and glaucoma has scarcely been
analyzed. To our knowledge, our study is the first to show that
higher level of skin AGEs, as measured with sAF, is
independently associated with glaucoma in a large and
unselected population of elderly people with a long history
of metabolic memory. Interestingly, Hondur et al.40 reported
that the level of AGEs was significantly higher in blood and
aqueous humor samples of glaucoma subjects than in samples
of age-matched nonglaucoma subjects. Furthermore, the level
of AGEs of glaucoma subjects was more than 3 times higher in
aqueous humor sample than in blood sample; thus, supporting
a potential intraocular generation of oxidative stress in
glaucoma subjects. Himori et al.38 recently published a study
analyzing the association between sAF and mean deviation
values of the visual field test in a Japanese population with
OAG and including essentially normal-tension glaucoma cases.
They observed that sAF was negatively correlated to mean
deviation values of the visual field test; thus, suggesting a role
of oxidative stress in the severity of glaucoma and visual field
loss. Our results are also in accordance with previously
published studies evaluating in vitro the accumulation of AGEs
on the optic nerve head or the retina from human donors.
Interestingly, Tezel et al.42 observed that accumulation of AGEs
and RAGE were more increased in older rather than younger
eyes and higher in glaucomatous eyes than in nonglaucoma-
tous eyes using immunofluorescence labeling on histologic
sections of eyes from age-matched glaucomatous and non-
glaucomatous donors. Furthermore, accumulation of AGEs and
RAGE was particularly observed on lamina cribrosa plates of
the optic nerve head, on the retinal ganglion cell layer, in the
glia, in the retinal distribution of Müller cells, and around blood
vessels. Furthermore, in previous studies, while Albon et al.62
observed a linear accumulation of AGEs with increasing age,
Amano et al.41 showed a higher accumulation of AGEs in
lamina cribrosa plates and around optic nerve head vessels.
Although the exact pathophysiologic process associating AGEs
and glaucoma is unclear, the higher extracellular accumulation
of AGEs in lamina cribrosa plates observed in glaucomatous
patients may change its biomechanical compliance and
consequently may in part increase the stress on optic nerve
axons leading to the characteristic glaucomatous optic nerve
head enlargement. Indeed, some studies postulate that
biomechanics of the lamina cribrosa and the peripapillary
sclera, especially stiffening, may play a significant role in
glaucomatous neuropathy by providing significant deforma-
tion, stress, and strain on surrounding tissues and structures
when pressure is applied.6,7,63 Hence, a chronic tissue
deformation could induce axoplasmic flow disruption, altered
optic nerve head blood flow and finally could lead to
connective tissue damage and remodeling. Finally, this chronic
injury of surrounding tissues of the lamina cribrosa under the
effect of IOP could lead to a progressive loss of optic nerve
head axons and glaucomatous neuropathy. Tezel et al.42 also
observed higher accumulation of AGEs associated with an
upregulation of RAGE around the optic nerve head and in the
retinal ganglion cell layer. The authors suggested that in
addition to direct cytotoxic effects of intracellular and
extracellular AGEs, RAGE may activate specific intracellular
pathways leading to oxidative stress, glial activation, and
ganglion cell dysfunction.42 Finally, Takeuchi et al.64 demon-
strated a direct cytotoxicity of AGEs on neuronal cells that also
could induce inflammation, oxidative stress, and generate free
radicals. Although the exact association between AGEs and
glaucoma would need further evaluations, the results of our
study—performed in vivo—supports all this experimental
evidence suggesting an influence of AGEs in the pathophysi-
ologic process of glaucoma.
Moreover, by estimating the long-term accumulation of
AGEs in long-lived proteins, sAF measurements may act as a
potential additional biomarker of oxidative stress activity in
glaucoma onset or progression. Unlike blood or aqueous
humor samples that measure circulating AGEs levels on a short
period of time, sAF measurements enable a noninvasive
estimation of AGEs accumulation over a long period of time,
and could thus represent a better biomarker of cumulative
metabolic stress and a potential additional predictive factor for
glaucoma. However, although sAF was significantly and
independently associated with glaucoma in the present study,
our results would need further evaluation of the clinical
validity of sAF measurements as a risk factor for glaucoma.
Although population-based study are designed to limit the risk
of participant selection bias that could lead to an overestima-
tion of results, the number of potential confounding factors in
a general population of elderly people, as general diseases,
increases and could limit the level of significance of
associations in a multivariate model. Thus, an appropriate
case-control study including an equivalent number of partic-
ipants with and without glaucoma, and matched on age and
potential confounding factors as general chronic diseases
would provide additional information on the discriminating
performances of sAF for glaucoma. Additionally, a longer
follow-up of our cohort of participants is needed to confirm
this association. Finally, the influence of cumulative metabolic
stress in glaucoma progression remains unclear and a
prospective study with a longitudinal follow-up of glaucoma
participants with sAF measurements at baseline could provide
valuable clinical information on the role of oxidative stress in
glaucoma progression.
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In the multivariate analysis, we also observed a strong
association between smoking and glaucoma. There was a
tendency toward a dose-dependent relationship with a
stronger association for the group of 20 or higher pack-years
exposure than for the group of 1 to 20 pack-years exposure.
Although smoking is an important risk factor for several
diseases, the association with glaucoma remains controver-
sial.65,66 In a meta-analysis evaluating the association between
smoking and glaucoma, Zhou et al.65 did not find any
significant pooled adjusted relative risk between current
smoker and former smoker or between current smoker and
never smoker. Inconsistency in determining association
between smoking and glaucoma results from limitations mainly
related to selective survival biases of the population sample
with a lower life expectancy associated to the smoker group.
As glaucoma is an age-related eye disease with an increasing
incidence with age, the survival difference between partici-
pants with smoking exposure and participants without
smoking exposure would tend to underestimate a potential
association between glaucoma and smoking. Our population
sample of elderly people had a long history of smoking
exposure and, despite the high mean age of our population,
still 34.5% (n ¼ 157) of the included participants reported a
smoking exposure. Hence, we hypothesize that our study
could be less affected by the selective survival bias associated
with smoking or that glaucoma could be associated to longer
smoking exposure. These findings would need further
exploration to be confirmed.
Although we have demonstrated that higher levels of sAF
are independently associated with glaucoma in a large and
unselected population of elderly people in which metabolic
activity had been recorded over a long period, our study may
have some limitations that need to be considered. The first
limitation is related to the cross-sectional nature of our study
that could limit the causality relationship between higher
levels of sAF and glaucoma. However, as suggested in previous
studies, sAF reflects AGEs accumulation in skin collagen, and
could therefore be considered as a long-term metabolic marker
or a predictive factor of disease or complications.33–37 Hence, a
long-term follow-up of our population of participants is needed
to strengthen the association between higher levels of skin
AGEs and glaucoma, and could also assess the role of sAF as a
potential long-term biomarker for incidence or progression of
glaucoma.
Another potential limitation to our results is related to the
representativeness of our population sample of elderly people.
Indeed, we could have selective survival biases related to the
elevated mean age of our sample, which tends to be healthier.
However, at this follow-up, the representativeness of our
population sample has been compared with the database of
INSEE for Bordeaux area population and there was no
significant difference in age, sex distribution, residency
location, and loneliness index.46 Furthermore, demographic
characteristics were not significantly different between includ-
ed and nonincluded participants of the study (Table 1) and the
prevalence of glaucoma we found was similar to those
observed in other studies.67–69 Hence, our findings need to
be replicated in another population sample to confirm all these
associations.
The method we used to identify glaucoma participants
could also be another potential limitation. Although Foster et
al.48 glaucoma diagnosis classification is a validated and well-
recognized method to define glaucoma in epidemiologic
studies, this method based on the subjective evaluation of
VCDR would tend to underestimate glaucoma prevalence by
potentially missing mild glaucoma cases having the lowest
VCDR values. Furthermore, this definition does not take into
account more recent methods of optic nerve head evaluation
including the use of OCT. Indeed, since the Foster et al.48
publication, several studies have demonstrated diagnostic
performances of OCT for glaucoma that could improve
diagnosis classification.45,70 However, in our study, VCDR
measurements were interpreted in duplicate by two specially
trained technicians masked to clinical information to limit the
risk of misclassification. Furthermore, the methodology of our
study was approved in 2006 and before publications of
population-based studies evaluating OCT diagnostic perfor-
mances for glaucoma. As the aim of our population-based study
was to assess the association of age-related eye diseases with
nutritional, environmental, genetic, or vascular factors and
with a longitudinal follow-up of participants approximately
every 2 years, we assume that our constant definition of
glaucoma during the study follow-up is the most appropriate
method to demonstrate all these associations.
Finally, although the AGE-reader enables a noninvasive in
vivo measurement of the accumulation of fluorescent AGEs in
skin collagen and also shows a strong correlation with several
fluorescent and even nonfluorescent AGEs measured on skin
biopsy, this device does not provide quantitative information
on specific AGEs concentration but estimates a group of
several AGEs that have progressively accumulated in the skin.
Furthermore, it can also measure some other autofluorescent
proteins not related to AGEs.21,71,72 Indeed, some other
fluorophores such as keratin, vitamin D, or lipofuscin, the
latter being involved in the aging process as well as in the
formation of AGEs, are within the range of excitation light of
the AGE-reader.11 Additionally, some other nonfluorescent
chromophores such as melanin or hemoglobin may also have
influenced sAF measurements.73 Our population sample of
elderly people has a higher mean age than that observed in
other published studies with a cumulative exposure to
metabolic activity over a longer period.22–32,38 Thus, it could
have led to a higher accumulation of AGEs in skin collagen
and also other fluorophores and chromophores that progres-
sively accumulates with increasing age. Hence, we cannot
exclude a higher confounding influence of these non-AGEs
components on sAF measurements in our population of
elderly people than that observed in younger population
sample. However, by showing an association with chronic
age-related disease or its complications, the measurement
provided by the AGE-reader has demonstrated its clinical
value in numerous studies.22–31,33–37 Thus, we assume that
our results are clinically relevant in glaucoma, but would also
probably need further exploration, including longitudinal sAF
measurements and an independent assessment of skin
content of AGEs and lipofuscin or melanin on skin biopsy,
in an attempt to cross-validate these findings in our
population sample composed of elderly people. These
explorations could confirm these results and determine
which AGEs are particularly involved or how they could
influence the pathogenesis of the disease. In addition, sAF
measurements cannot be performed in the darkest skin
phototypes V and VI because of their low reflectance.
Moreover, although a specific algorithm has been used to
correct for differences among skin phototypes I and IV, the
vast majority of studies have been conducted in Caucasian
subjects and an effect of skin color on sAF measurements
cannot be excluded.21 Skin phototype of participants was not
collected in our study due to ethical issues related to the
record of skin color in France. Although our population
sample was mainly composed of subjects from Caucasian
origin, future studies should take skin color (including in
phototypes I–IV) into account as a potential confounder.
Studies are also needed in subjects from other ethnicities, to
confirm the interest of sAF measurements in these popula-
tions.
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In conclusion, in this population-based study of elderly
people, increased sAF, as well as smoking, were independently
associated with glaucoma. By measuring in vivo and noninva-
sively long-term accumulation of AGEs in skin collagen, sAF
could be a long-term biomarker of glaucoma. Furthermore,
several experimental studies reported that formation, accumu-
lation or action of AGEs could be inhibited directly or indirectly
and that the binding of AGEs to RAGE could also be
inhibited.74,75 Thus, our findings associated with other
published evidence on the role of AGEs in glaucoma
pathogenesis might contribute to enhance glaucoma preven-
tion or treatment strategy, and therefore might improve
glaucoma-related visual impairment. Indeed, if this association
is confirmed and in addition with other reported risk factors
for glaucoma, sAF measurements might contribute to charac-
terize earlier patients with higher risk of glaucoma onset or
glaucoma progression. However, further investigations are
needed to confirm and replicate this association, to determine
the role of sAF as a long-term biomarker or potential predictor
of the disease during the follow-up of our study, and to evaluate
the correlation between sAF and glaucoma severity in an
appropriate case-control study involving more glaucoma
patients.
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France), Université de Bordeaux (Bordeaux, France), Fondation
Voir et Entendre (Paris, France) and CNSA (Caisse Nationale pour
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